Energetic returns | Recovery play
News covered in our update here includes an introduction to a small company that has secured a huge contract in a very big market. Elsewhere, there were excellent results from a medical device company but results from one large AIM company didn’t offer much of a guide to its future potential. A renewable energy company has also been transformed following a series of acquisitions. Read on here for our usual forthright observations. (Premium)
NIOX: great results and plenty of delightful cash NIOX Group (AIM: NIOX), amedical device company focused on point of care asthma diagnosis and management, announced impressive results for the year ended 31 December 2023. NIOX’s stated mission is to improve asthma diagnosis and management by greater patient access to FeNO testing. Asthma is one of the biggest healthcare issues globally with 340 million sufferers, many of whom are undiagnosed or are misdiagnosed. NIOX designs and commercialises medical devices for the measurement of FeNO, a precise biomarker for asthma. Its market leading device, NIOX VERO®, is increasingly recognised by healthcare professionals…